Gene · 155
Papers3,802
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 3,802
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Light-Based Molecular Tools to Precisely Monitor and Operate β-Adrenoceptors. | Med Res Rev | 2026 | 41121750 | PubTator, text mining | PubMed |
| Effect of Oral Mirabegron on Catheter-Related Bladder Dysfunction After Elective Gynecological Surgery Under General Anesthesia: A Randomized, Placebo-Controlled, Double-Blind Study. | Int Urogynecol J | 2026 | 41042318 | PubTator, text mining | PubMed |
| Aging hematopoietic system: Mechanisms, disorders, and therapeutic frontiers. | Chin Med J (Engl) | 2026 | 40999561 | PubTator, text mining | PubMed |
| A bibliometric study of the most-cited research articles and reviews in Naunyn-Schmiedeberg's Archives of Pharmacology (1969-2024). | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 40748476 | PubTator, text mining | PubMed |
Persistent bothersome urinary frequency following stereotactic body radiation therapy for clinically localized prostate cancer: rationale for prophylactic β3-agonist in men with elevated baseline international prostate symptom scores. | Front Oncol | 2025 | 41626149 | PubTator, text mining | PubMed |
| Emerging opportunities in ROP therapy: from inhibiting pathological vessel growth to promoting physiological vascularization. | Front Med (Lausanne) | 2025 | 41601770 | PubTator, text mining | PubMed |
| Therapeutic Potential of the β3-Adrenergic Receptor and Its Ligands in Cardiovascular Diseases. | Int J Mol Sci | 2025 | 41465273 | PubTator, text mining | PubMed |
| Letter by Hang et al Regarding Article, "An NRF2/β3-Adrenoreceptor Axis Drives a Sustained Antioxidant and Metabolic Rewiring Through the Pentose-Phosphate Pathway to Alleviate Cardiac Stress". | Circulation | 2025 | 41428796 | PubTator, text mining | PubMed |
Response by Balligand and Michel to Letter Regarding Article, "An NRF2/β3-Adrenoreceptor Axis Drives a Sustained Antioxidant and Metabolic Rewiring Through the Pentose-Phosphate Pathway to Alleviate Cardiac Stress". | Circulation | 2025 | 41428795 | PubTator, text mining | PubMed |
| Toward a Multi-Trait Genetic Panel Targeting Training, Rehabilitation, and Chronic Disease Prevention: A Narrative Review. | Genes (Basel) | 2025 | 41300761 | PubTator, text mining | PubMed |
| GLIS3 rs7034200 and ADRB3 rs4994 genetic variants associated with an increased risk of gestational diabetes mellitus in Chinese women: a case-control study. | BMC Pregnancy Childbirth | 2025 | 41272565 | PubTator, text mining | PubMed |
| RETRACTION: Beta3-Adrenergic Receptor Activation Alleviates Cardiac Dysfunction in Cardiac Hypertrophy by Regulating Oxidative Stress. | Oxid Med Cell Longev | 2025 | 41142502 | PubTator, text mining | PubMed |
| Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells. | Invest New Drugs | 2025 | 41108330 | PubTator, text mining | PubMed |
| Cetacean loss of the master adipose tissue regulator β3-adrenergic receptor may underlie their thick blubber and an Oligocene radiation and dispersal. | Nat Commun | 2025 | 41107224 | PubTator, text mining | PubMed |
| Adipose m6A reader YTHDF2 promotes obesity, insulin resistance, and liver steatosis by suppressing β-adrenergic signaling and lipolysis. | Cell Rep | 2025 | 41100256 | PubTator, text mining | PubMed |
| A Prospective Paired Comparison Trial of Mirabegron and Anticholinergics in Patients With Low Bladder Compliance. | Int Neurourol J | 2025 | 41077793 | PubTator, text mining | PubMed |
| Rational Use of Bethanechol in Dogs and Cats with Bladder Dysfunction. | Vet Sci | 2025 | 41012843 | PubTator, text mining | PubMed |
| Nanomedicine targeting PPAR in adipose tissue macrophages improves lipid metabolism and obesity-induced metabolic dysfunction. | Sci Adv | 2025 | 41004576 | PubTator, text mining | PubMed |
| The thermogenic effect of mirabegron ingestion during cool conditions. | Front Physiol | 2025 | 41000106 | PubTator, text mining | PubMed |
| Mitochondrial uncoupling, energy substrate utilization, and brown adipose tissue as therapeutic targets in cancer. | NPJ Metab Health Dis | 2025 | 40983641 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/155/papers?page=4